Phase III trial primary endpoint met for respiratory syncytial virus (RSV) vaccine, nirsevimab

In Phase III MELODY trial, this long-acting antibody designed to act as passive immunisation, met the primary endpoint in medically attended lower respiratory tract infections (LRTI) caused by RSV in healthy late preterm and term infants.

Source:

Biospace Inc.